GT Biopharma, Inc. GTBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-294.13
Altman Z″ — distress risk · distress
-0.8%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$28.4M | — | — | $5.8M |
| 2024 | — | -$13.2M | — | — | -$1.7M |
| 2023 | — | -$7.6M | — | — | $7.5M |
| 2022 | — | -$20.9M | — | — | $11.7M |
| 2021 | — | -$58.0M | — | — | $21.9M |
| 2020 | $0 | -$28.3M | — | — | -$29.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Breen Michael Martin | Executive Chairman/Interim CEO | 2023-08-11 | Grant | 200,000 | $0.29 |
| Ohri Manu | CFO & Secretary | 2023-08-11 | Grant | 200,000 | $0.29 |
| Ohri Manu | CFO & Secretary | 2023-08-11 | J | 200,000 | $0.29 |
| Ohri Manu | CFO & Secretary | 2023-08-11 | J | 200,000 | $0.29 |
| Breen Michael Martin | Executive Chairman/Interim CEO | 2023-04-11 | Buy | 50,000 | $0.50 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -294.13 (distress)
- Working capital / assets 0.714
- Retained earnings / assets -89.304
- EBIT / assets -1.532
- Equity / liabilities 2.495
Source: SEC EDGAR filings · CIK 0000109657 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.